Effects of the combined hormonal replacement drug estradiol valerate/levonorgestrel on climacteric complaints, endometrium and lipid profile of peri- and postmenopausal women

被引:4
|
作者
Georgiev, DB
Golbs, S
Goudev, A
机构
[1] Second Obstet Gynecol Hosp, Sofia 1504, Bulgaria
[2] Jenapharm GmbH & Co KG, Jena, Germany
[3] Med Univ Sofia, Dept Internal Med 2, Prevent Cardiol Clin, Sofia, Bulgaria
来源
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 2001年 / 23卷 / 04期
关键词
climacteric complaints; endometrium; estradiol valerale/levonorgestrel; hormone replacement therapy; plasma lipids and lipoproteins;
D O I
10.1358/mf.2001.23.4.634644
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of the combined hormone replacement (HRT) drug estradiol valerate/levonorgestrel (Klimonorm(R)) on climacteric complaints , endometrial status and lipid profile was studied in 100 peri- and postmenopausal women aged between 41 and 57 years. The duration of therapy was 6 months. The following parameters were investigated: Kuppermann index, endometrial thickness, duration of bleeding, arterial blood pressure, body weight and serum lipids and lipoproteins (total cholesterol TC, LDL cholesterol, HDL cholesterol, and triglycerides [TG]). A separate analysis was made for 27 patients who had abnormal lipid status before treatment. total cholesterol above 6.0 mmol/l and/or LDL of more than 3.5 mmol/l was considered abnormal and those patients were labeled as "high risk". The results showed a statistically significant reduction in the severity of climacteric symptoms (Kupperman index). A large decrease in this score was observed during the first 3 months of treatment (from 27.9 at the start to mean values of 9.3, p<0.001). A further slight decrease of the score to 4.0 (p<0.001) was seen after 6 months of treatment. Endometrial thickness did not change. At the start of the treatment the mean duration of bleeding was 5.1 +/-0.3 days and at the end of the 6 month it was 3.8 +/-0.2 days (p<0.001), Klimonorm(R) favorably affected lipid profile. TC decreased significantly during the therapy: by 5.2% (p<0.05) in all women and 7.1% (p<0.05) in the high risk group, LDL cholesterol decreased slightly: by 4.5% (p<0.05) in all women and was more pronounced in the high risk group (7.0%, p<0.01). HDL cholesterol increased by 12.1% (p<0.01) in all women and by 14.7% (p<0.001) in the high risk group. TG were elevated slightly by 9.5% (p<0.05) in all women and 3.9% (p>0.05) in the high risk group. LDL/HDL ratio decreased from 2.7 to 2.3 in all women and from 3.0 to 2.4 (p<0.05) in the high risk group. No significant changes in systolic and diastolic blood pressure were recorded. Body weight did not change significantly during the treatment period. (C) 2001 Prous Science. All rights reserved.
引用
收藏
页码:197 / 202
页数:6
相关论文
共 50 条
  • [1] Changes in psychic and somatic well-being and cognitive capabilities of peri- and postmenopausal women after the use of a hormone replacement drug containing estradiol valerate and levonorgestrel
    Rudolph, I
    Zimmermann, T
    Kaminski, K
    Jandova, K
    Borovsky, B
    Ahrendt, HJ
    Golbs, S
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2000, 22 (01): : 51 - 56
  • [2] Lipid profile in peri- and postmenopausal women with sleep disorders
    Semenova, N.
    Madaeva, I.
    Kolesnikov, S.
    Kolesnikova, L.
    JOURNAL OF SLEEP RESEARCH, 2020, 29 : 278 - 279
  • [3] Lipid profile, inflammation, and oxidative status in peri- and postmenopausal women
    Taleb-Belkadi, Ouarda
    Chaib, Hadjer
    Zemour, Lakhdar
    Fatah, Azzedine
    Chafi, Belkacem
    Mekki, Khedidja
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 (12) : 982 - 985
  • [4] Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders
    Saisai Li
    Linjuan Ma
    Yang Song
    Jiehong Zheng
    Yuqun Cai
    Hong Xu
    Peiqiong Chen
    Wenxian Xu
    Yizhou Huang
    Tongyun Qi
    Chunming Li
    Ketan Chu
    Yibing Lan
    Ling Xu
    Jianhong Zhou
    BMC Endocrine Disorders, 21
  • [5] Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders
    Li, Saisai
    Ma, Linjuan
    Song, Yang
    Zheng, Jiehong
    Cai, Yuqun
    Xu, Hong
    Chen, Peiqiong
    Xu, Wenxian
    Huang, Yizhou
    Qi, Tongyun
    Li, Chunming
    Chu, Ketan
    Lan, Yibing
    Xu, Ling
    Zhou, Jianhong
    BMC ENDOCRINE DISORDERS, 2021, 21 (01)
  • [6] Efficacy and tolerability of the hormone replacement drug estradiol valerate/levonorgestrel in the treatment of menopausal syndrome in Thai women
    Chittacharoen, A
    Domhardt, R
    Manonai, J
    Golbs, S
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 645 - 651
  • [7] Effects of a combination of 2 mg estradiol valerate and 3 mg dienogest on coagulation, lipid profile, and glucose metabolism in postmenopausal women
    Gräser, T
    Müller, A
    Druckman, R
    Oettel, M
    DRUGS OF TODAY, 2001, 37 : 87 - 99
  • [8] Transdermal Estradiol and Lipid Profile: Effects on a Specific Group of Brazilian Postmenopausal Women
    Callejon, Daniel R.
    Rios, Danyelle Romana A.
    Franceschini, Silvio A.
    Toloi, Maria Regina T.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2009, 93 (06) : 617 - 622
  • [9] Organ of hearing and balance in peri- and postmenopausal women. Effects of hormone replacement therapy on hearing and balance in peri- and post-menopausal women: The current state of knowledge
    Orendorz-Fraczkowska, Krystyna
    Temporale, Hanna
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (06): : 751 - 755
  • [10] Efficacy of moxonidine and its combination with hormonal replacement therapy on plasma lipid profile in postmenopausal women
    Dadashova, G. M.
    Bakhshaliyev, A.
    CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 : 140C - 141C